End-of-day quote
Korea S.E.
23:00:00 24/03/2024 GMT
|
5-day change
|
1st Jan Change
|
2,020
KRW
|
+9.54%
|
|
-.--%
|
-67.58%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
321,353
|
337,280
|
712,301
|
842,433
|
544,996
|
516,267
|
Enterprise Value (EV)
1 |
309,494
|
379,655
|
741,191
|
861,281
|
588,273
|
567,785
|
P/E ratio
|
-15.6
x
|
-26.8
x
|
-16.5
x
|
-15.8
x
|
-10.1
x
|
104
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
51.3
x
|
38.5
x
|
68.7
x
|
64.7
x
|
48.4
x
|
47.9
x
|
EV / Revenue
|
49.4
x
|
43.4
x
|
71.5
x
|
66.1
x
|
52.2
x
|
52.7
x
|
EV / EBITDA
|
-22.9
x
|
-19.4
x
|
-21.9
x
|
-22.1
x
|
-14.7
x
|
-10.9
x
|
EV / FCF
|
-15.6
x
|
-16.4
x
|
-39.5
x
|
-52
x
|
-42.3
x
|
-21.4
x
|
FCF Yield
|
-6.41%
|
-6.1%
|
-2.53%
|
-1.92%
|
-2.36%
|
-4.67%
|
Price to Book
|
9.21
x
|
3.14
x
|
6.01
x
|
7.12
x
|
6.37
x
|
4.61
x
|
Nbr of stocks (in thousands)
|
49,630
|
62,459
|
67,838
|
75,050
|
79,562
|
82,868
|
Reference price
2 |
6,475
|
5,400
|
10,500
|
11,225
|
6,850
|
6,230
|
Announcement Date
|
18/03/19
|
19/03/20
|
19/03/21
|
21/03/22
|
20/03/23
|
05/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
6,269
|
8,749
|
10,372
|
13,020
|
11,263
|
10,769
|
EBITDA
1 |
-13,503
|
-19,545
|
-33,851
|
-38,988
|
-40,149
|
-52,328
|
EBIT
1 |
-14,434
|
-24,496
|
-41,197
|
-47,440
|
-49,653
|
-60,829
|
Operating Margin
|
-230.24%
|
-279.98%
|
-397.21%
|
-364.36%
|
-440.86%
|
-564.84%
|
Earnings before Tax (EBT)
1 |
-22,409
|
-11,343
|
-43,138
|
-50,095
|
-56,658
|
-37,485
|
Net income
1 |
-20,453
|
-11,429
|
-41,439
|
-50,336
|
-53,505
|
5,261
|
Net margin
|
-326.27%
|
-130.63%
|
-399.54%
|
-386.6%
|
-475.06%
|
48.85%
|
EPS
2 |
-415.2
|
-201.5
|
-636.1
|
-709.8
|
-679.4
|
60.00
|
Free Cash Flow
1 |
-19,826
|
-23,163
|
-18,775
|
-16,554
|
-13,904
|
-26,494
|
FCF margin
|
-316.26%
|
-264.74%
|
-181.02%
|
-127.14%
|
-123.46%
|
-246.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/03/19
|
19/03/20
|
19/03/21
|
21/03/22
|
20/03/23
|
05/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
42,375
|
28,889
|
18,848
|
43,276
|
51,518
|
Net Cash position
1 |
11,859
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-2.168
x
|
-0.8534
x
|
-0.4834
x
|
-1.078
x
|
-0.9845
x
|
Free Cash Flow
1 |
-19,826
|
-23,163
|
-18,775
|
-16,554
|
-13,904
|
-26,494
|
ROE (net income / shareholders' equity)
|
-54.7%
|
-16.1%
|
-36.4%
|
-42.6%
|
-54.8%
|
-37.1%
|
ROA (Net income/ Total Assets)
|
-14.5%
|
-12.1%
|
-13.3%
|
-15.4%
|
-17.7%
|
-21.5%
|
Assets
1 |
141,261
|
94,332
|
311,794
|
327,572
|
301,976
|
-24,500
|
Book Value Per Share
2 |
703.0
|
1,721
|
1,748
|
1,576
|
1,076
|
1,353
|
Cash Flow per Share
2 |
16.70
|
204.0
|
226.0
|
155.0
|
74.10
|
7.960
|
Capex
1 |
638
|
11,723
|
857
|
1,379
|
926
|
590
|
Capex / Sales
|
10.17%
|
133.99%
|
8.27%
|
10.59%
|
8.22%
|
5.48%
|
Announcement Date
|
18/03/19
|
19/03/20
|
19/03/21
|
21/03/22
|
20/03/23
|
05/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -67.58% | 128M | | +7.52% | 113B | | +11.38% | 106B | | -12.64% | 22.22B | | +0.44% | 22.27B | | -4.18% | 19.43B | | -37.85% | 17.87B | | -8.58% | 17.24B | | +37.41% | 12.52B | | -23.95% | 8.34B |
Bio Therapeutic Drugs
|